• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Correction to: Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in multiple myeloma: a meta-analysis.对《环磷酰胺联合粒细胞集落刺激因子与单用粒细胞集落刺激因子两种干细胞动员方案治疗多发性骨髓瘤的疗效、安全性及生存结局比较：一项荟萃分析》的勘误
Ann Hematol. 2021 Feb;100(2):575. doi: 10.1007/s00277-021-04427-w.
2
Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in multiple myeloma: a meta-analysis.两种干细胞动员方案（环磷酰胺联合 G-CSF 或单独 G-CSF）在多发性骨髓瘤中的疗效、安全性和生存结局比较：一项荟萃分析。
Ann Hematol. 2021 Feb;100(2):563-573. doi: 10.1007/s00277-020-04376-w. Epub 2021 Jan 6.
3
Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.环磷酰胺联合粒细胞集落刺激因子用于多发性骨髓瘤患者造血干细胞动员
J Clin Apher. 2016 Oct;31(5):423-8. doi: 10.1002/jca.21421. Epub 2015 Sep 5.
4
Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study.在多发性骨髓瘤中，用于干细胞动员的初治普乐沙福加粒细胞集落刺激因子与环磷酰胺加粒细胞集落刺激因子的疗效和成本分析研究。
Bone Marrow Transplant. 2016 Apr;51(4):546-52. doi: 10.1038/bmt.2015.322. Epub 2016 Jan 4.
5
Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone.在接受包含硼替佐米、环磷酰胺和地塞米松的统一诱导方案治疗的多发性骨髓瘤患者中，不同干细胞动员方式后的植入情况比较。
Ann Hematol. 2017 Mar;96(3):461-467. doi: 10.1007/s00277-016-2897-2. Epub 2016 Dec 24.
6
Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF.基于诱导治疗反应的多发性骨髓瘤动员方案选择：单纯粒细胞集落刺激因子（G-CSF）与大剂量环磷酰胺加G-CSF对比
Leuk Lymphoma. 2016;57(6):1389-97. doi: 10.3109/10428194.2015.1102240. Epub 2015 Nov 16.
7
Improved progression-free and event-free survival in myeloma patients undergoing PBSCH receiving a cyclophosphamide + G-CSF regimen than G-CSF alone.与单独使用粒细胞集落刺激因子（G-CSF）相比，接受环磷酰胺+G-CSF方案的自体骨髓干细胞移植（PBSCH）骨髓瘤患者的无进展生存期和无事件生存期得到改善。
Int J Hematol. 2018 May;107(5):559-567. doi: 10.1007/s12185-018-2408-4. Epub 2018 Jan 31.
8
Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.粒细胞集落刺激因子与粒细胞巨噬细胞集落刺激因子联合强化化疗用于多发性骨髓瘤外周血干细胞动员和自体移植的随机对照研究
Biol Blood Marrow Transplant. 2004 Jun;10(6):395-404. doi: 10.1016/j.bbmt.2004.02.001.
9
Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma.影响多发性骨髓瘤患者外周血干细胞采集的因素。
Bone Marrow Transplant. 1996 Jun;17(6):937-41.
10
Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.在新型治疗时代，使用普乐沙福和粒细胞集落刺激因子（G-CSF）动员多发性骨髓瘤患者的外周血干细胞，与使用低剂量环磷酰胺和G-CSF进行动员相比，具有更高的疗效，但成本显著更高。
J Clin Apher. 2013 Oct;28(5):359-67. doi: 10.1002/jca.21280. Epub 2013 Jun 14.

引用本文的文献

1
Prolonged infusion time of cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) as a mobilization regimen may improve mobilization efficiency in newly diagnosed multiple myeloma patients: a single center experience.环磷酰胺联合粒细胞集落刺激因子（G-CSF）长时间输注作为动员方案可能会提高初诊多发性骨髓瘤患者的动员效率：单中心经验。
Ann Med. 2023;55(2):2289603. doi: 10.1080/07853890.2023.2289603. Epub 2023 Dec 17.
2
Poor Mobilizers in Lymphoma but Not Myeloma Patients Had Significantly Poorer Progression-Free Survival after Autologous Stem Cell Transplantation: Results of a Large Retrospective, Single-Center Observational Study.淋巴瘤患者中动员不佳者而非骨髓瘤患者在自体干细胞移植后无进展生存期显著更差：一项大型回顾性单中心观察性研究的结果
Cancers (Basel). 2023 Jan 18;15(3):608. doi: 10.3390/cancers15030608.

Correction to: Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in multiple myeloma: a meta-analysis.

作者信息

Wang Liwen, Xiang Hongxian, Yan Yuhan, Deng Zuqun, Li Hui, Li Xin, Liu Jing

机构信息

Department of Hematology, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan Province, China.

Xiangya School of Medicine, Central South University, Changsha, 410013, Hunan Province, China.

出版信息

Ann Hematol. 2021 Feb;100(2):575. doi: 10.1007/s00277-021-04427-w.

DOI:10.1007/s00277-021-04427-w
PMID:33459825
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8025259/
Abstract
摘要